Last edition
News about "Travere Therapeutics"
Travere Secures Full US FDA Approval for FILSPARI
Travere Therapeutics secures full US FDA approval for FILSPARI (sparsentan) to treat FSGS, expanding access to over 100,000 patients with a therapy aligned with KDIGO guidelines.
Travere Therapeutics | 15/04/2026 | By News Bureau
Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan
In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
Travere Therapeutics | 01/02/2025 | By Abha | 661
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy